Correlation Between New-Onset Atrial Fibrillation and Cancer
2Monica
2George

Soliman, 1Carlos Rodríguez Pellicer, 1Alejandro Herreros-Pomares, 1Aurelio Quesada Dorador, 1Francisco Javier Quesada Ocete,
1,3,4Fernando Vidal-Vanaclocha

Washington University School of Medicine and Health Sciences, 1University of Valencia General Hospital, 3GWU Cancer Center, 4GWU Department of Biochemistry and Molecular Medicine

INTRODUCTION
An increase in the incidence of new-onset Atrial Fibrillation
(AF) has been noticed in patients in acute inflammatory states
and with local inflammatory conditions. Cancer, through
inflammatory mediators and autonomic dysfunction, may
favor the appearance of AF. Some studies have found that
cancer patients generally had a 47% higher risk of developing
AF than non-cancer patients, and that this risk is increased
only in the first 90 days following cancer diagnosis.
Furthermore, patients with a first episode of AF could have a
higher risk of developing cancer. In fact, AF has been
proposed as a marker for occult neoplasia. However, more
studies are needed to study the association of AF and cancer,
as it is not yet known whether this is a causal association or
simply that the two pathologies share the same
pathophysiological mechanisms as their etiology. The
objective of this study was to analyze the incidence of cancer
2 years after the first episode of AF in patients at the General
University Hospital of Valencia, and to search for relevant
variables that allow for differentiating patients who will
develop cancer from patients who will not.

MATERIALS AND METHODS

• Out of 712 patients with new-onset AF, 35 (4.91%) were
found to have a malignancy 2 years after index episode
• Patients without cancer presented more frequently with
typical symptoms such as palpitations (32.64%) compared to
14.28% in the cancer group, which is a statistically significant
difference (p=0.025).
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Graph 1. Proportion of each type of cancer to the total
number of patients diagnosed with cancer in the 2 years
following the debut of AF
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Table 1. Baseline Characteristics of Cancer-Free and Cancer
Patients
VARIABLE

No cancer (n=677) (95.08%)

With cancer 2 years after index episode
(n=35) (4,91%)

p-value

Demographics
Age

74.14 +/- 12.73

78.68 +/- 12.75

0.039

<65 years

141 (20.82)

4 (11.43)

0.178

65-74 years

158 (23.33)

5 (14.28)

0.213

75-85 years

248 (36.63)

16 (45.71)

0.278

>85 years

130 (19.20)

10 (28.57)

0.173

VARIABLE

Sex

No cancer (n=677) (95.08%)

F: 418 (61.74)
M: 259 (38.26)

With cancer 2 years after index episode
(n=35) (4.91%)

Urological
11%
head and Neck
3%

Gynacological
6%

Digestive
9%

p-value

F: 23 (65.71)
M: 12 (34.28)

0.723

Cardiovascular risk factors
HTA

523 (77.25)

25 (71.43)

0.414

DM

242 (35.74)

10 (28.57)

0.470

Smoking

74 (10.93)

3 (8.57)

1.000

Obesity

55 (8.12)

2 (5.71)

1.000

279 (41.21)

13 (37.14)

0.633

13 (1.92)

0 (0)

0.408

Alcohol
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CONCLUSION

Non-solid
34%

Dyslipidemia

• The population sample was obtained from a database in
which the encoded anonymized information of 2022
episodes of AF treated in the Emergency Service of the
Consortium General University Hospital of Valencia
(CHGUV) was collected from 1 January 2010 to December
31, 2015.
• The electrocardiograms associated with the AF episode
were reviewed, including only those with a confirmed
diagnosis of AF.
• Exclusion criteria included a previous history of AF,
previous antiarrhythmic or anticoagulant treatment,
previous history of cancer (including non-melanoma skin
neoplasms), and an urgent precipitating condition that
justified the AF episode (i.e. infections, sepsis, acute
coronary syndromes, critically ill patients).
• The final sample was 712 patients.
• Retrospective follow-up of patients for at least 2 years was
carried out through the EMR of the hospital to note the
development of cancer.
• Student T-test was applied for the comparison of
quantitative variables and the Chi-square test for the
comparison of qualitative variables of this final sample of
cancer vs. non-cancer subjects (95% Confidence Interval).
• Since there was no control group, the results were
compared with the incidence of cancer in our
environment, which was extracted in 2012 from the
Spanish Society of Medical Oncology (SEOM).

RESULTS (Cont.)

RESULTS

Comorbidities
SAHS

21 (3.10)

0 (0)

0.290

COPD

58 (8.56)

4 (11.42)

0.535

Renal Insufficiency

70 (10.33)

1 (2.86)

0.242

Hepatic Insufficiency

7 (1.03)

0 (0)

1.000

Enf. Rheumatic

35 (5.16)

2 (5.71)

0.702

IBD

2 (0.29)

0 (0)

0.747

The number of neoplasms diagnosed in the study period was
2.45 cases per 100 people/year. When compared with the
incidence of cancer in Spain in 2012 (0.46 cases per 100
people/year) as notified by the SEOM, the difference is found
to be statistically significant. Non-solid neoplasms comprised
the largest type of frequency, representing 34.28% of the total.
Colorectal and breast neoplasia were shown to be the second
in frequency, but with a markedly lower percentage than the
former (both with 14.28%).

Cardiovascular history
Arteriopathy

36 (5.31)

0 (0)

0.249

MI

55 (8.12)

4 (11.42)

0.522

CVA

65 (9.6)

2 (5.71)

0.764

Bleeding

23 (3.57)

2 (5.71)

0.467

LVEF previous cancellation

15 (2.21)

0 (0)

0.373

Cardiopathy

33 (4.87)

3 (8.57)

0.413

100 (14.77)

3 (8.57)

0.459

Mc. Vault. Mitral

60 (8.86)

2 (5.71)

0.760

Mc. Vault. Aortic

49 (7.23)

4 (11.42)

0.321

Mc. Dilated

11 (1.70)

0 (0)

0.447

Mc. Ischemic

47 (6.94)

5 (14.28)

0.169

Hypertrophic Mc.

28 (4.34)

0 (0)

0.219

IC

VARIABLE
Mc. Hypertensive
CHA2DS2-Vasc

No cancer (n=677) (95.08%)

With cancer 2 years after index episode
(n=35) (4.91%)

Graph 2. Incidence of cancer by age in Spain in 2012 and in
the two years after the debut of AF in our study. CHGUV:
Consortium General University Hospital of Valencia
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The average age of cancer patients in the study period (78.68 +
12.75) was higher than that presented by those who did not
develop cancer (74.14 + 12.73), this difference being
statistically significant (p=0.039). Looking at patients over 65
years of age, this group represented 88.57% of cancer patients,
while in patients without cancer it represented 79.17%. The rest
of the variables analyzed, including cardiovascular risk factors,
a history of smoking or alcohol, or inflammation-sensitive labs
(troponin, leukocytes, CRP) did not present significant
differences.

0.28
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There was a higher incidence of cancer in patients with AF
over 65 years of age compared to those under this age (2.17
versus 0.28 cases per 100 people/year). When compared by
age groups, it was observed that there is a higher incidence of
cancer in our sample in comparison to the general population
both in individuals under 65 years of age (0.28% vs 0.18%)
and those over 65 years of age (2.17% vs 0.28%).

This study detected an unusually high incidence of cancer in
patients with a first diagnosis of AF. Specifically, the annual
incidence of 2.45 cases per 100 people/year after the debut of
AF is 6.1 times more than the risk in the general Spanish
population, being especially higher in those over 65 years of
age. Although other studies had also come to a similar
conclusion, this study differs in that it used stricter exclusion
criteria to avoid confounding bias, and it relied on an
electrocardiographic diagnosis of AF, which is essential to
ensure the correct diagnosis of the arrhythmia. A major
limitation to this study was the absence of a control group to
compare the incidence of cancer to. Univariate and
multivariate analysis did not detect a relevant variable that
allows for differentiating patients who will present with
cancer from patients who will not. However, with the results
of this study, surveillance of cancer should be considered in
patients presenting with new-onset AF, especially in those
over 65 years of age with atypical symptoms. Further studies
are needed to explore the relationship between these two
pathologies as it is still unknown whether there is a causal
relationship between both conditions or if both simply share
the same pathophysiological mechanism involved in their
genesis.
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